Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Ramzi Adil"'
Autor:
Lei Shi, William Shen, Mindy I. Davis, Ke Kong, Phuong Vu, Supriya K. Saha, Ramzi Adil, Johannes Kreuzer, Regina Egan, Tobie D. Lee, Patricia Greninger, Jonathan H. Shrimp, Wei Zhao, Ting-Yu Wei, Mi Zhou, Jason Eccleston, Jonathan Sussman, Ujjawal Manocha, Vajira Weerasekara, Hiroshi Kondo, Vindhya Vijay, Meng-Ju Wu, Sara E. Kearney, Jeffrey Ho, Joseph McClanaghan, Ellen Murchie, Giovanna S. Crowther, Samarjit Patnaik, Matthew B. Boxer, Min Shen, David T. Ting, William Y. Kim, Ben Z. Stanger, Vikram Deshpande, Cristina R. Ferrone, Cyril H. Benes, Wilhelm Haas, Matthew D. Hall, Nabeel Bardeesy
Publikováno v:
Nature Cancer. 4:365-381
Autor:
Nabeel Bardeesy, Robert T. Manguso, Hongwu Zheng, Rahul M. Kohli, Vikram Deshpande, Brandon Nicolay, Lipika Goyal, Cristina R. Ferrone, Mathias Heikenwälder, Tong Wang, Russell W. Jenkins, Rodrigo Saad-Berreta, Yi Sun, Sebastien Ronseaux, Christine Hudson, Mirian Fernández-Vaquero, María García-Beccaria, William Shen, Meiqi Luo, Qibiao Wu, Yuanli Zhen, Vajira Weeresekara, Krishna Seshu Tummala, Amaya Pankaj, Ramzi Adil, Kira E. Olander, Emily Kessler, Ting-Yu Wei, Vindhya Vijay, Joshua Merritt, Juan Dubrot, Lei Shi, Meng-Ju Wu
Supplementary table from Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4591e78e7671b476dda13e33c1b01770
https://doi.org/10.1158/2159-8290.22541389
https://doi.org/10.1158/2159-8290.22541389
Autor:
Nabeel Bardeesy, Cyril H. Benes, Lipika Goyal, Dejan Juric, Andrew X. Zhu, John D. Gordan, James R. Stone, Charlotte S. Walmsley, Daniel E. McLoughlin, Christopher J. Pinto, Islam Baiev, Vikram Deshpande, Cristina R. Ferrone, Xunqin Yin, Meng-Ju Wu, Regina Egan, Joshua Merritt, Ramzi Adil, Patricia Greninger, Phuong Vu, Lei Shi, Yuanli Zhen, Qibiao Wu
Supplementary Table from EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::931e04b614aba9b77872a721a0f534da
https://doi.org/10.1158/2159-8290.22540895
https://doi.org/10.1158/2159-8290.22540895
Autor:
Nabeel Bardeesy, Robert T. Manguso, Hongwu Zheng, Rahul M. Kohli, Vikram Deshpande, Brandon Nicolay, Lipika Goyal, Cristina R. Ferrone, Mathias Heikenwälder, Tong Wang, Russell W. Jenkins, Rodrigo Saad-Berreta, Yi Sun, Sebastien Ronseaux, Christine Hudson, Mirian Fernández-Vaquero, María García-Beccaria, William Shen, Meiqi Luo, Qibiao Wu, Yuanli Zhen, Vajira Weeresekara, Krishna Seshu Tummala, Amaya Pankaj, Ramzi Adil, Kira E. Olander, Emily Kessler, Ting-Yu Wei, Vindhya Vijay, Joshua Merritt, Juan Dubrot, Lei Shi, Meng-Ju Wu
Supplementary Figure from Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1f285ec531b322829e126b3586d7fc7
https://doi.org/10.1158/2159-8290.22541395.v1
https://doi.org/10.1158/2159-8290.22541395.v1
Autor:
Nabeel Bardeesy, Robert T. Manguso, Hongwu Zheng, Rahul M. Kohli, Vikram Deshpande, Brandon Nicolay, Lipika Goyal, Cristina R. Ferrone, Mathias Heikenwälder, Tong Wang, Russell W. Jenkins, Rodrigo Saad-Berreta, Yi Sun, Sebastien Ronseaux, Christine Hudson, Mirian Fernández-Vaquero, María García-Beccaria, William Shen, Meiqi Luo, Qibiao Wu, Yuanli Zhen, Vajira Weeresekara, Krishna Seshu Tummala, Amaya Pankaj, Ramzi Adil, Kira E. Olander, Emily Kessler, Ting-Yu Wei, Vindhya Vijay, Joshua Merritt, Juan Dubrot, Lei Shi, Meng-Ju Wu
Isocitrate dehydrogenase 1 mutations (mIDH1) are common in cholangiocarcinoma. (R)-2-hydroxyglutarate generated by the mIDH1 enzyme inhibits multiple α-ketoglutarate–dependent enzymes, altering epigenetics and metabolism. Here, by developing mIDH1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28dbb03d0373c9d903a08ccbd12df350
https://doi.org/10.1158/2159-8290.c.6549628.v1
https://doi.org/10.1158/2159-8290.c.6549628.v1
Autor:
Nabeel Bardeesy, Cyril H. Benes, Lipika Goyal, Dejan Juric, Andrew X. Zhu, John D. Gordan, James R. Stone, Charlotte S. Walmsley, Daniel E. McLoughlin, Christopher J. Pinto, Islam Baiev, Vikram Deshpande, Cristina R. Ferrone, Xunqin Yin, Meng-Ju Wu, Regina Egan, Joshua Merritt, Ramzi Adil, Patricia Greninger, Phuong Vu, Lei Shi, Yuanli Zhen, Qibiao Wu
Supplementary Figure from EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::422abc098d7c3a0f2950cc928525d9be
https://doi.org/10.1158/2159-8290.22540901
https://doi.org/10.1158/2159-8290.22540901
Autor:
Nabeel Bardeesy, Cyril H. Benes, Lipika Goyal, Dejan Juric, Andrew X. Zhu, John D. Gordan, James R. Stone, Charlotte S. Walmsley, Daniel E. McLoughlin, Christopher J. Pinto, Islam Baiev, Vikram Deshpande, Cristina R. Ferrone, Xunqin Yin, Meng-Ju Wu, Regina Egan, Joshua Merritt, Ramzi Adil, Patricia Greninger, Phuong Vu, Lei Shi, Yuanli Zhen, Qibiao Wu
FGFR inhibitors are approved for the treatment of advanced cholangiocarcinoma harboring FGFR2 fusions. However, the response rate is moderate, and resistance emerges rapidly due to acquired secondary FGFR2 mutations or due to other less-defined mecha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dd84f4a0eca53b00c987cfcb283dbf4
https://doi.org/10.1158/2159-8290.c.6549500.v1
https://doi.org/10.1158/2159-8290.c.6549500.v1
Autor:
Emily Kessler, Rodrigo Saad-Berreta, Hongwu Zheng, Vikram Deshpande, Krishna S. Tummala, Brandon Nicolay, William Shen, Ramzi Adil, Meng-Ju Wu, Juan Dubrot, Lipika Goyal, Vajira Weeresekara, Amaya Pankaj, Mathias Heikenwalder, Tong Wang, Mirian Fernandez-Vaquero, María García-Beccaria, Ting-Yu Wei, Kira E Olander, Sebastien Ronseaux, Vindhya Vijay, Qibiao Wu, Yuanli Zhen, Christine Hudson, Nabeel Bardeesy, Lei Shi, Rahul M. Kohli, Meiqi Luo, Yi Sun, Russell W. Jenkins, Robert T. Manguso, Cristina R. Ferrone, Joshua Merritt
Publikováno v:
Cancer Discovery. 12:812-835
Isocitrate dehydrogenase 1 mutations (mIDH1) are common in cholangiocarcinoma. (R)-2-hydroxyglutarate generated by the mIDH1 enzyme inhibits multiple α-ketoglutarate–dependent enzymes, altering epigenetics and metabolism. Here, by developing mIDH1
Autor:
Qibiao Wu, Yuanli Zhen, Lei Shi, Phuong Vu, Patricia Greninger, Ramzi Adil, Joshua Merritt, Regina Egan, Meng-Ju Wu, Xunqin Yin, Cristina R. Ferrone, Vikram Deshpande, Islam Baiev, Christopher J. Pinto, Daniel E. McLoughlin, Charlotte S. Walmsley, James R. Stone, John D. Gordan, Andrew X. Zhu, Dejan Juric, Lipika Goyal, Cyril H. Benes, Nabeel Bardeesy
Publikováno v:
Cancer discovery, vol 12, iss 5
Cancer Discov
Cancer Discov
FGFR inhibitors are approved for the treatment of advanced cholangiocarcinoma harboring FGFR2 fusions. However, the response rate is moderate, and resistance emerges rapidly due to acquired secondary FGFR2 mutations or due to other less-defined mecha
Autor:
Brandon Nicolay, Juan Dubrot, Lei Shi, Sebastien Ronseaux, Robert T. Manguso, Rohini Narayanaswamy, Nabeel Bardeesy, Qibiao Wu, Meng-Ju Wu, Christine Hudson, Ramzi Adil, Joshua Merritt
Publikováno v:
Cancer Research. 80:1810-1810
Intrahepatic cholangiocarcinoma (ICC) is a cancer of the liver bile ducts, which has been rising in incidence and carries a 5-year survival rate of less than 10%. Mutations in isocitrate dehydrogenase 1 and 2 (mIDH1/2) are among the most common genet